Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 154,671 shares, a drop of 55.8% from the July 15th total of 349,646 shares. Based on an average trading volume of 769,462 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.0% of the company’s shares are short sold.

Azitra Price Performance

AZTR traded down $0.00 during trading on Friday, reaching $0.14. 1,041,981 shares of the company’s stock were exchanged, compared to its average volume of 1,476,759. The company’s fifty day moving average price is $0.16 and its 200-day moving average price is $0.19. Azitra has a fifty-two week low of $0.10 and a fifty-two week high of $1.40.

Azitra (NYSEAMERICAN:AZTR) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). As a group, analysts anticipate that Azitra will post -0.25 earnings per share for the current year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.